相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study
Matteo Filippini et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)
Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: Effectiveness comparative study
Mercedes Arenere Mendoza et al.
MEDICINA CLINICA (2010)
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis
C. Trocme et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
B. Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients
C. Popa et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Disease Remission State in Patients Treated With the Combination of Tumor Necrosis Factor Blockade and Methotrexate or With Disease-Modifying Antirheumatic Drugs A Clinical and Imaging Comparative Study
Benazir Saleem et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Vicki Oldfield et al.
BIODRUGS (2009)
Periodontal Therapy Reduces the Severity of Active Rheumatoid Arthritis in Patients Treated With or Without Tumor Necrosis Factor Inhibitors
P. Ortiz et al.
JOURNAL OF PERIODONTOLOGY (2009)
E-selectin, Interleukin 18, Serum Amyloid A, and Matrix Metalloproteinase 9 Are Associated with Clinical Response to Golimumab plus Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Sudha Visvanathan et al.
JOURNAL OF RHEUMATOLOGY (2009)
The Tumor Necrosis Factor-α-blocking Agent Infliximab Inhibits Interleukin 1β (IL-1β) and IL-6 Gene Expression in Human Osteoblastic Cells
Estella Musacchio et al.
JOURNAL OF RHEUMATOLOGY (2009)
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population
Naoki Iwamoto et al.
MODERN RHEUMATOLOGY (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis
Antonio Julia et al.
PLOS ONE (2009)
Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis
Faruk Uguz et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2009)
Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
M. L. Hetland et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
C. A. Wijbrandts et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases
I. Cavazzana et al.
AUTOIMMUNITY REVIEWS (2008)
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Alberto Alonso-Ruiz et al.
BMC MUSCULOSKELETAL DISORDERS (2008)
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis
Boxiong Tang et al.
CLINICAL THERAPEUTICS (2008)
Immunization of patients with rheumatoid arthritis with antitumor necrosis factorα therapy and methotrexate
Hans-Peter Brezinschek et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Impact of three anti-TNFα biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients
H. Bacquet-Deschryver et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment
Tiina Levalampi et al.
RHEUMATOLOGY INTERNATIONAL (2008)
Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis
Anne Grimstvedt Kvalvik et al.
JOINT BONE SPINE (2007)
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
Andrew Nesbitt et al.
INFLAMMATORY BOWEL DISEASES (2007)
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
S. Bombardieri et al.
RHEUMATOLOGY (2007)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice:: a systematic retrospective study of 709 patients
C. Salliot et al.
RHEUMATOLOGY (2007)
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
Florenzo Iannone et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab - Results from the ASPIRE trial
JS Smolen et al.
ARTHRITIS AND RHEUMATISM (2006)
Long term safety of etanercept in elderly subjects with rheumatic diseases
R Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies
MH Schiff et al.
DRUGS & AGING (2006)
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
AL Weaver et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) - A randomized, controlled trial
YPM Goekoop-Ruiterman et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab therapy in established rheumatoid arthritis: An observational study
PV Voulgari et al.
AMERICAN JOURNAL OF MEDICINE (2005)
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement - A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
JS Smolen et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate
RN Maini et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Impact of shared epitope genotype and ethnicity on erosive disease - A meta-analysis of 3,240 rheumatoid arthritis patients
JD Gorman et al.
ARTHRITIS AND RHEUMATISM (2004)
Biomedicines to reduce inflammation but not viral load in chronic HCV - what's the sense?
EM Chuang et al.
TRENDS IN BIOTECHNOLOGY (2004)
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
C Ferraro-Peyret et al.
ARTHRITIS RESEARCH & THERAPY (2004)
The safety of anakinra in high-risk patients with active rheumatoid arthritis - Six-month observations of patients with comorbid conditions
MH Schiff et al.
ARTHRITIS AND RHEUMATISM (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
R van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
